Intermittent claudication described

Characterized "the role of the carotid arteries in the causation of vascular lesions of the brain" and described "attacks of threatened hemiplegia and cerebral intermittent claudication"... 

Clein ei al. (1962) have recently described a further blind control trial of a-tocopherol in intermittent claudication. The abstract published to date gives very few data, but one series of 20 patients with femeropopliteal occlusion and poor distal bed showed 10 failures out of 10 on placebo and only 2 failures out of 10 on a-tocopherol, a highly significant difference. 

The new millennium found lower extremity arterial disease (LEAD) and intermittent claudication in particular, pharmacotherapeutically orphan. Pharmacologically, intermittent claudication has been an orphan since it was first described many decades ago. Intermittent claudication, the cardinal symptom of LEAD occurs in 35 to 50% of patients with known LEAD documented by noninvasive diagnostic methods (1). The development of effective pharmacotherapy for treating claudication has lagged behind that for treating angina pectoris and other manifestations of myocardial ischemia. 

---